藥明康德(02359.HK):擬認繳Sofinnova Capital X的2000萬歐元的A類份額
格隆匯7月22日丨藥明康德(02359.HK)公佈,2021年7月22日,公司全資子企業WuXi PharmaTech Healthcare Fund I L.P.(以下簡稱"WuXi FundI")與Sofinnova Partners(以下簡稱"管理公司")簽署Subscription Agreement(以下簡稱"認購協議"),約定由WuXi FundI認繳Sofinnova Capital X(以下簡稱"投資基金")的2,000萬歐元的A類份額,成為A類份額持有人,約佔已募集投資基金份額的9.7%(WuXi FundI所持投資基金股份比例將隨投資基金後續從第三方投資機構募資而進一步稀釋)。截至公吿日,WuXi FundI尚未支付投資款,後續WuXi FundI將以自有資金根據投資基金章程的要求履行投資款的支付義務。
投資基金預計募集總額不超過 4.5 億歐元。WuXi Fund I此次認繳2,000萬歐元后,投資基金已募集 2.06億 歐元資金。投資基金為一家依據法國法律成立的專業私募股權投資基金(Professional Private Equity Investment Fund),主要專注於在世界範圍內投資生命科學領域(特別是生物醫藥及醫療器械行業)的中小型企業。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.